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Background
The efficacy of mAb and their fragments in cancer therapy
depends on their capacity to recognize tumor associated
antigens. From a clinical point of view, intact mAb are
employed in the treatment of lymphoid tumors whereas
antibody fragments such as Fabs or F(ab')2 can be the ther-
apeutic of choice for solid tumors due to shorter circulat-
ing half life and a higher tumor penetration, both
characteristics well suited in a radio immunotherapy
(RIT) approach.
Ovarian cancer is the leading cause of death among gyne-
cological tumors. Standard first line therapy consists of
surgery followed by chemotherapy cycles. About 90% of
patients relapse with a 5-year survival rate of 5–20% [1].
So far, second line chemotherapy after clinical relapse has
shown limited efficacy. With the advancement of the
recombinant biotechnology, a novel approach based on
human monoclonal antibody immunotherapy has began
to be investigated. The alfa folate receptor (αFR), which is
a 38000 Dalton anchored membrane protein, is over
expressed in more than 90% of ovarian carcinoma cells,
and in 60% of other gynecological carcinomas [2]. In con-
trast to normal epithelial cells, ovarian carcinoma cells
express this receptor on their external surface making it
accessible for binding to monoclonal antibodies.
The basic concept of our project is to produce a full
human F(ab')2 fragment for radio immunotherapy to spe-
cifically target the αFR. The candidate Fab fragment was
isolated and cloned into an Escherichia coli expression vec-
tor. After classical shaking flask cultures expression the
recombinant strain was taken to lab scale fermentation
plant where different feeding strategies were designed to
increase the production yield [3].
Results
Fermentation scale up is aimed at the manufacture of
large quantities of product while maintaining the specific
yields and quality. We report the development of a Fed-
batch fermentation process evaluated at 10 and 300 liters
scale, for the production of functional Fab' monomer in E.
coli, at high cell density fermentation, under DO-stat con-
trol strategy using a synthetic medium. The construction
of a stable bicistronic expression vector and a proprietary
host-plasmid pair allows us to obtain both high level
expression (up to 100 mg/L) and correctly folded protein
expressed in the periplasm but straightforwardly in the
broth supernatant were the Fab' accumulate. To identify
process-specific stress factors and to understand the phys-
iological responses to the vessel specific physical condi-
tions, the process was evaluated at 10 liters scale for
animal grade production and with comparable results, at
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Microbial Cell Factories 2006, 5(Suppl 1):P29300 L scale in a clinical grade cGMP plant. Despite sub-
strate oscillation due to the DO-stat mechanism, whitch
final results is a linear feeding, at both scale the plasmid
stability and cell vitality, measured by means of a biomass
monitor (Aber instrument) were maintained. Neither lysis
nor protease production were detected during the fermen-
tation course.
Typical process parameter and analytical data coming
from 10 and 300 L are reported in figure 1 (a-d) and in
Figure 2 (a-b). In Table 1 mean yield coefficient at both
scales are calculated.
All activities carried out for 300 L production scale are
developed in a GMP compliance pilot plant. At the end of
a) Effect of DO-Stat strategy on: (♦) biomass level (OD600), (■) residual substrate concentration and (▲) Fab' accumulation at 10 lit rs scale fermen ation (HPLC analysis)Figure 1
a)Effect of DO-Stat strategy on: (♦) biomass level (OD600), (■) residual substrate concentration and (▲) Fab' accumulation at 
10 liters scale fermentation (HPLC analysis); b typical curve of (–) DO, (–) pH, (---) OD600 and (---) Inductor (FEED) during 
DO-Stat fermentation; c representative curves of (–) conductivity and (–) capacitance in fermentation broth and Oxygen and 




































OD600 nm Substrate Fab'
Induction







































































Chan 3 Oxygen Chan 4  CO2




































b)Page 2 of 3
(page number not for citation purposes)
Microbial Cell Factories 2006, 5(Suppl 1):P29fermentation both pH and temperature are adjusted to
trigger contaminant proteins precipitation. The remaining
soluble proteins were recovered from the biomass by tan-
genzial flow filtrations (TFF) and purified to homogene-
ity. Fab biological activity was monitored by BIACORE,
FACS and ELISA analysis.
Conclusion
Altogether the reported data confirmed the technical fea-
sibility of 10 to 300 L scale-up along with the process
robustness and recombinant Fab' production consistency.
Several fed-batch methods for carbon source feeding
maintaining low by-products levels were developed. Most
of these are based on mathematical models that foresee
growth patterns and expected demand for nutrients. Our
results suggest that a DO-stat feeding strategy is an effi-
cient, straightforward scalable, physiological and elegant
way of carrying out fermentation process to obtain both
high expression level and properly folded protein. The
Fab' quantity and quality produced by the described proc-
ess were adequate to justify the production of clinical tri-
als material. Moreover some critical parameters for scale
up were identified.
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Table 1: Parameters for mean yield coefficient calculation at 10 and 300 L scale fermentation.
Fermentation Time OD600 DCW Substrate Fab Fab DCW Substrate YXS YPX YPS
scale (l) (h) g.l-1 g.l-1 g.l-1 g.l-1.h g.l-1.h g.l-1.h g.g-1 g.g-1 g.g-1
(X) (S) (P) (rP) (rX) (-rS)
10 36 137 36.4 186 0.0642 0.00178 1.01 5.16 0.196 0.0018 0.00035
300
3 8 10 2.9 15 0.36
30 6 18 5.8 30 0.96
300 37 136 36.2 190 0.0685 0.00185 0.98 5.13 0.190 0.0019 0.00036
a Effect of DO-Stat strategy on: (♦) biomass level (OD600), (■) residual substrate concentration and (▲) Fab' accumulation at 300 liters scale fermentation (HPLC analysis)Figur 2
a Effect of DO-Stat strategy on: (♦) biomass level (OD600), (■) residual substrate concentration and (▲) Fab' accumulation at 
300 liters scale fermentation (HPLC analysis);  bWestern blot of different samples taken throughout the induction phase.
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